2016
DOI: 10.1128/aac.01043-16
|View full text |Cite
|
Sign up to set email alerts
|

Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay

Abstract: e Middle East respiratory syndrome (MERS) is an emerging infectious disease associated with a relatively high mortality rate of approximately 40%. MERS is caused by MERS coronavirus (MERS-CoV) infection, and no specific drugs or vaccines are currently available to prevent MERS-CoV infection. MERS-CoV is an enveloped virus, and its envelope protein (S protein) mediates membrane fusion at the plasma membrane or endosomal membrane. Multiple proteolysis by host proteases, such as furin, transmembrane protease seri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

8
305
0
7

Year Published

2017
2017
2022
2022

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 329 publications
(320 citation statements)
references
References 39 publications
8
305
0
7
Order By: Relevance
“…In this context, it is noteworthy that the serine protease inhibitor camostat mesylate, which blocks TMPRSS2 activity (Kawase et al, 2012;Zhou et al, 2015), has been approved in Japan for human use, but for an unrelated indication. This compound or related ones with potentially increased antiviral activity (Yamamoto et al, 2016) could thus be considered for off-label treatment of SARS-CoV-2-infected patients.…”
Section: Discussionmentioning
confidence: 99%
“…In this context, it is noteworthy that the serine protease inhibitor camostat mesylate, which blocks TMPRSS2 activity (Kawase et al, 2012;Zhou et al, 2015), has been approved in Japan for human use, but for an unrelated indication. This compound or related ones with potentially increased antiviral activity (Yamamoto et al, 2016) could thus be considered for off-label treatment of SARS-CoV-2-infected patients.…”
Section: Discussionmentioning
confidence: 99%
“…Expression of TMPRSS2 at the cell surface induces both virus entry into cells and cell-cell fusion of S protein-expressing cells (4,10,27). Furthermore, these phenomena are suppressed by the serine protease inhibitors camostat mesylate and nafamostat mesylate (4,10,28). In addition, other extracellular proteases, such as trypsin and elastase, activate the MERS-CoV S protein in a manner similar to that of TMPRSS2 (10).…”
Section: Discussionmentioning
confidence: 99%
“…In addition, camostat at a concentration of 10 mM impairs MERS-CoV entry 15-fold in Vero-TMPRSS2 cells, and the amount of viral RNA in the culture supernatant of Calu-3 cells is reduced 270-fold in the presence of 100 mM camostat at three days post MERS-CoV infection [22]. More recently, nafamostat, a serine protease inhibitor, was reported, to block MERS-CoV infection in vitro via inhabiting the activity of TMPRSS2, and reduced viral entry by 100-fold at a concentration of as low as 1 nM, which is more effective than camostat [74].…”
Section: Approved Drugs For Other Diseases With Tmprss2 Inhibitory Acmentioning
confidence: 99%